Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study

Background/Objectives: Menopause is associated with symptoms that may negatively affect quality of life (QoL). This study evaluated the effects of a Hops (8-prenylnaringenin, 8-PN) and Cimicifuga-based multicomponent food supplement on menopausal symptoms and QoL in postmenopausal women. Methods: A prospective, unicentric, non-comparative, observational study was conducted in postmenopausal women aged 45–65 years with climacteric symptoms. Participants received two daily capsules (one DAY and one NIGHT) of a Hops (8-PN) and Cimicifuga-based food supplement (Libicare® Meno) for 12 weeks. QoL was assessed using the Cervantes short-form (C-SF) scale as the primary endpoint. Secondary endpoints included evaluation of general health status (EUROQOL), mood (Visual Analog Scale [VAS]), plasma vitamin D levels, satisfaction, and tolerability. Assessments were performed at baseline, 4, and 12 weeks. Results: Thirty-three women were evaluated. Total C-SF score decreased from 41.13 ± 20.2 at baseline to 36.37 ± 21.5 and 33.70 ± 18.6 at 4 and 12 weeks, respectively, reaching statistical significance at week 12 (p = 0.046). The improvement was particularly evident in the vasomotor subdomain. Mood also improved significantly, with VAS scores decreasing from 5.18 ± 2.7 to 3.12 ± 2.2 (p = 0.001) and 3.30 ± 1.9 (p < 0.001) at 4 and 12 weeks, respectively. Vitamin D levels increased from 26.57 ± 8.22 to 32.75 ± 5.65 ng/mL at week 12. No serious adverse events were reported, and 51.5% of participants were satisfied or very satisfied with treatment. Conclusions: Libicare® Meno was associated with improvements in QoL and mood in symptomatic postmenopausal women, with good tolerability and satisfaction.

Authors

Institutions

Publication Details

Journal
Clinics and Practice
Published
2026-11-18
DOI
https://doi.org/10.3390/clinpract16110217
Primary Topic
Menopause: Health Impacts and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study

Santiago Palacios Gil‐Antuñano, Marieta Ramírez Bermúdez, E. Garcia, Mariella Lilue Bajares et al.
2 links
Clinics and Practice
Menopause: Health Impacts and Treatments
article

Effectiveness of a Novel Hops (8-Prenylnaringenin) and Cimicifuga-Based Combination Food Supplement in Alleviating Climacteric Symptoms and Enhancing Quality of Life in Postmenopausal Women: Results from the LIBIRTY Clinical Study

Santiago Palacios Gil‐Antuñano, Marieta Ramírez Bermúdez, E. Garcia, Mariella Lilue Bajares, María Teresa Martín Pedraza
article en

Abstract

Background/Objectives: Menopause is associated with symptoms that may negatively affect quality of life (QoL). This study evaluated the effects of a Hops (8-prenylnaringenin, 8-PN) and Cimicifuga-based multicomponent food supplement on menopausal symptoms and QoL in postmenopausal women. Methods: A prospective, unicentric, non-comparative, observational study was conducted in postmenopausal women aged 45–65 years with climacteric symptoms. Participants received two daily capsules (one DAY and one NIGHT) of a Hops (8-PN) and Cimicifuga-based food supplement (Libicare® Meno) for 12 weeks. QoL was assessed using the Cervantes short-form (C-SF) scale as the primary endpoint. Secondary endpoints included evaluation of general health status (EUROQOL), mood (Visual Analog Scale [VAS]), plasma vitamin D levels, satisfaction, and tolerability. Assessments were performed at baseline, 4, and 12 weeks. Results: Thirty-three women were evaluated. Total C-SF score decreased from 41.13 ± 20.2 at baseline to 36.37 ± 21.5 and 33.70 ± 18.6 at 4 and 12 weeks, respectively, reaching statistical significance at week 12 (p = 0.046). The improvement was particularly evident in the vasomotor subdomain. Mood also improved significantly, with VAS scores decreasing from 5.18 ± 2.7 to 3.12 ± 2.2 (p = 0.001) and 3.30 ± 1.9 (p < 0.001) at 4 and 12 weeks, respectively. Vitamin D levels increased from 26.57 ± 8.22 to 32.75 ± 5.65 ng/mL at week 12. No serious adverse events were reported, and 51.5% of participants were satisfied or very satisfied with treatment. Conclusions: Libicare® Meno was associated with improvements in QoL and mood in symptomatic postmenopausal women, with good tolerability and satisfaction.

Clinics and PracticeVol. 16(11)
Instituto Palacios (ES)
Good health and well-being
Menopause: Health Impacts and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon